Activated CLL cells regulate IL-17F-producing Th17 cells in miR155-dependen and outcome-specific manners

Chronic lymphocytic leukemia (CLL) results from expansion of a COS' B cell clone that requires interactions with other cell types, including T cells. Moreover, patients with CLL have elevated levels of circulating IL-17A(+) and IL-17F(+) CD4(+) T (Th17) cells, with higher numbers of IL-17A(+) Th17 cells correlating with better outcomes. We report that CLL Th17 cells expressed more miR155, a Th17-differentiation regulator, than control Th17 cells, despite naive CD4(+) T (Tn) cell basal miR155 levels being similar in both. We also found that CLL cells directly regulated miR155 levels in Tn cells, thereby affecting Th17 differentiation, by documenting that coculturing Tn cells with resting or activated (B-act) CLL cells altered the magnitude and direction of T cell miR155 levels; CLL B-act cells promoted IL-17A(+) and IL-17F(+) T cell generation by an miR155-dependent mechanism, confirmed by miR155 inhibition; coculture of Tn cells with CLL B-a(ct) cells led to a linear correlation between the degree and direction of T cell miR155 expression changes and production of IL-17F but not IL-17A; and B-act cell-mediated changes in Tn cell miR155 expression correlated with outcome, irrespective aC of IGHV mutation status, a strong prognostic indicator. These results identify a potentially unrecognized CLL B-act cell-dependent mechanism, upregulation of Tn cell miR155 expression and subsequent enhancement of IL-17F(+) Th17 generation, that favors better clinical courses.